INSTRUCTIONS FOR USE - PLEASE READ CAREFULLY!

Supraviran® 250 i.v.

Active substance: aciclovir sodium (equiv. to 250 mg aciclovir)

GRÜNENTHAL

COMPOSITION
1 vial of SUPRAVIRAN 250 i.v. contains:

ACTIVE COMPONENTS
274.4 mg aciclovir sodium = 250 mg aciclovir

OTHER COMPONENTS
None

DOSAGE FORM AND CONTENTS
1 vial with 274.4 mg dry substance for the preparation of an infusion solution.

Prevents the growth of certain viruses.

Grünenthal GmbH - D-52222 Stolberg (Tel.: 0241/569-0, Fax: 0241/569-1522)

INDICATIONS
Primary genital herpes and infections of the skin and mucous membranes caused by herpes simplex viruses in patients with congenital immune deficiency or secondary immune defects, such as those that might occur in the course of treatment with immunosuppressive agents (e.g. after organ transplantation) or cytostatic agents.

CONTRAINDICATIONS

When not to use SUPRAVIRAN 250 i. v.?
If you are allergic to drugs containing aciclovir, you should not use SUPRAVIRAN 250 i .v..
During pregnancy your doctor will only prescribe SUPRAVIRAN 250 i.v. if absolutely necessary.

What must be taken into account during pregnancy and breast-feeding?
Pregnancy: if you are pregnant, your doctor will only prescribe SUPRAVIRAN 250 i.v. after assessing the benefit/risk ratio.
Breast-feeding: SUPRAVIRAN 250 i.v. passes into the breast milk; therefore breast-feeding should not be carried out during treatment with SUPRAVIRAN 250 i.v..

What about administration in children?
Children may be treated with aciclovir.

PRECAUTIONS AND WARNINGS

What precautions must be taken into account?
If you suffer from chronic kidney insufficiency or impaired kidney function, it may be necessary to reduce the dose of SUPRAVIRAN 250 i.v..
If a high dose of aciclovir is given intravenously, kidney function should be checked. This applies particularly to patients with impaired kidney function and patients who do not drink much liquid.

What must be taken into account when driving, operating machines or working without a firm hold?
Direct effects of aciclovir on reactions or road safety are not known. However, you must remember that in rare cases side-effects such as drowsiness, dizziness and hallucinations may occur particularly if your kidney function is damaged.

INTERACTIONS

Which other drugs may have an influence on the effect of SUPRAVIRAN 250 i. v.?
Probenecid - a drug given if the level of uric acid in the blood is too high - reduces the removal of aciclovir via the kidneys. This may prolong the effect of SUPRAVIRAN 250 i. v..
Please remember that this may also apply, if you have recently taken any drugs.

DOSAGE, MODE AND DURATION OF ADMINISTRATION
Unless otherwise prescribed by your doctor, the following dosage of SUPRAVIRAN 250 i.v. applies. Please follow the instructions, otherwise SUPRAVIRAN 250 i.v. will not be fully effective.

How much and how often should you take SUPRAVIRAN 250 i. v.?
Newborn babies, babies up to 3 months, children from the age of 12 years and adults receive the same dose related to kg body weight.
In children from the age of 3 months to 12 years SUPRAVIRAN 250 i.v. should be give in a dose equivalent to the body surface in order to avoid any underdosage.
The following table will give you an idea of the dosage:
Newborn babies, babies up to 3 months, children from the age of 12 years and adults receive the intravenous infusion according to the following scheme:
Patients with a normal immune system

Indication	Single dose (mg/kg bw) aciclovir	Average period of treatment (in days)	Daily dose with normal kidney function (mg/kg bw)
Primary genital herpes	5	5*	15

**Longer periods of treatment are possible in individual cases and depend on the clinical condition of the patient.*

Patients with immune defects

Indication	Single dose (mg/kg bw) aciclovir	Average period of treatment (in days)	Daily dose with normal kidney function (mg/kg bw)
Herpes simplex infections	5	5*	15

**Longer periods of treatment are possible in individual cases and depend on the clinical condition of the patient.*

Children from the age of 3 months to 12 years receive the intravenous infusion according to the following dosage scheme:
Patients with a normal immune system

Indication	Single dose (mg aciclovir/m²)	Average period of treatment (in days)	Daily dose with normal kidney function (mg aciclovir/m²)
Herpes simplex infections *	250	5*	750

**Longer periods of treatment are possible in individual cases and depend on the clinical condition of the patient.*

Patients with immune defects

Indication	Single dose (mg aciclovir/m²)	Average period of treatment (in days)	Daily dose with normal kidney function (mg aciclovir/m²)
Herpes simplex infections	250	5*	750

** Longer periods of treatment are possible in individual cases and depend on the clinical condition of the patient.*

Patients with normal kidney function receive the single dose three times a day every 8 hours.

Patients with **restricted kidney function** receive a single dose according to the following scheme:

Creatinine clearance (ml/min/1.73 m2)	Serum creatinine (µmol/l/mg/dl)		Single dose interval
	Women	Men	
> 50	< 130/< 1.47	< 170/< 1.92	every 8 hours
50–25	130–280/1.47–3.17	170–370/1.92-4.18	every 12 hours
25–10	280–550/3.17–6.22	370–750/4.18–8.48	every 24 hours
10–0 (anuric)	> 550/> 6.22	> 750/> 8.48	half the single dose every 24 hours and after each blood wash

PREPARATION OF THE SUPRAVIRAN INFUSION SOLUTION

The contents of one vial are dissolved by adding 10 ml water for injections or physiological saline solution. This concentrated solution, or parts of it, are added immediately to at least 50 ml (maximum 250 ml) infusion solution.

The concentrated SUPRAVIRAN 250 i.v. solution has a pH value of about 11; therefore it should not be taken by mouth.

If SUPRAVIRAN 250 i.v. is given intravenously by means of an infusion pump, infusion solutions containing up to 2.5% aciclovir (25 mg aciclovir/ml) should be used.

For the infusion solution physiological saline is recommended that must not contain any additives other than SUPRAVIRAN 250 i.v.

SUPRAVIRAN 250 i.v. should be dissolved and added to the infusion solution immediately before being given.

After addition of SUPRAVIRAN 250 i.v. prepared infusion solutions can be stored at + 15 °C to + 25 °C for up to 12 hours.

Infusion solutions must **not** be stored in a refrigerator!

How and when should you use SUPRAVIRAN 250 i. v.?

SUPRAVIRAN 250 i.v. should be given as an intravenous infusion, not as a bolus injection .

Each single dose should be infused slowly over a period of one hour.

Particularly in patients with restricted kidney function - especially elderly patients - care should be taken to see that sufficient liquid is drunk during treatment.

How long should SUPRAVIRAN 250 i.v. be given?

The doctor decides on the duration of treatment. The table under "Dosage" gives an idea of the duration of treatment.

ERRORS IN ADMINISTRATION AND OVERDOSAGE

What should be done when too much SUPRAVIRAN 250 i.v. has been given (intentional or accidental overdosage)?

Poisoning has so far not been observed after overdosage. After the accidental administration of an intravenous dose of up to 80 mg/kg body weight no side-effects were observed.

Possible signs of poisoning are a decrease in peripheral leukocytes, a rise in liver enzyme values and central nervous reactions such as trembling and confusion.

Treatment of Poisoning:

The administration of drugs to increase the volume of urine and make it alkaline or blood wash.

SIDE-EFFECTS

Which side-effects may occur during treatment with SUPRAVIRAN 250 i.v.?

After administration of SUPRAVIRAN 250 i.v. the following side-effects have occasionally been observed: brief rise of urea and creatinine in the blood. In order to avoid this, the drug should be infused slowly over a period of about one hour, and not given as a bolus injection. In the event of kidney function disorders (which in exceptional cases may lead to acute kidney failure), the dose should be reduced or the preparation discontinued.

Care should be taken to see that sufficient liquid is drunk.

After accidental administration of Supraviran 250 i.v. into the tissues surrounding the vein, severe inflammation of the skin, and occasionally destruction of the areas of skin affected, have been observed.

Reversible neurological signs, such as confusion, hallucinations, restlessness, trembling, drowsiness, psychosis, fits and coma have been reported in connection with the intravenous administration of SUPRAVIRAN 250 i.v., mainly in cases where complications are present.

After the intravenous administration of SUPRAVIRAN 250 i.v. nausea and vomiting may occur, liver enzyme values may rise, and there have been reports of a fall in blood values, rash and fever during treatment.

If you experience side-effects that are not listed in this package insert, please inform your doctor or pharmacist.

NOTES AND DETAILS OF THE SHELF-LIFE OF THE DRUG

The expiry date of this pack is printed on the top flap of the box and the vial. Do not use the pack after this date!

Any unused remains of the dry substance or the concentrated solution must be discarded.

Any infusion solution prepared more than 12 hours previously must not be used.

If the prepared infusion solution becomes cloudy before or during the infusion, the infusion must be stopped and the infusion solution discarded.

SUPRAVIRAN 250 i.v. should not be stored at temperatures above 25 °C.

Please keep SUPRAVIRAN 250 i.v. out of children's reach!

DATE OF INFORMATION

April 1995